Open AccessExpression of Serum IL-22, IL-23, and TLR9 as Tumor Markers in Untreated Breast Cancer Patients
Author(s) -
Hanaa N. Abdullah,
Alia Gh. Abdulwahid
Publication year - 2020
Publication title -
international journal of drug delivery technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.133
H-Index - 9
ISSN - 0975-4415
DOI - 10.25258/ijddt.10.3.30
Subject(s) - medicine , breast cancer , tlr9 , malignancy , cancer , gastroenterology , oncology , biology , gene expression , gene , biochemistry , dna methylation
Breast cancer (BC) is the most common cancer among women and is the most important cause of death among them. Breast cancer is a common malignancy, accounting for one-third of women cancers in Iraq. To the best of our knowledge, little literature information is available on the participation of Interleukin-22 (IL-22), interleukin-23 (IL-23), and Toll-like receptor 9 (TLR9) in BC patients. Thus, the evaluation of serum IL-22, IL-23, and TLR9 level changes can add new information on their roles in breast cancer development and progression. The present study aimed to evaluate the clinical usefulness of IL-22, IL-23, and TLR9 as tumor markers in BC.Levels of circulating interleukin-22, IL-23, and TLR9 were estimated by the enzyme-linked immunoassay method. The serum level of IL-22 was highly significantly elevated in patients compared to the benign and healthy control groups (317.53 ± 14.33 vs. 68.73 ± 12.38 and 62.67 ± 19.11 pg/mL, p ≤ 0.05), but the difference between the benign tumor and healthy control groups means was not significant. Also, these results indicated that the mean level of IL-23 was higher significantly in breast cancer patients in comparison with the benign and healthy controls (887.89 ± 199.04 vs. 146.86 ± 84.26 and 72.26 ± 12.76 pg/mL, p ≤ 0.05). So, no significant difference was revealed between a benign tumor and healthy control groups (146.86 ± 84.26 and 72.26 ± 12.76 pg/mL, p andgt; 0.05). Finally, a serum level of TLR9 was significantly elevated in breast cancer patients in comparison with the control groups (16.89 ± 0.75 vs. 9.97 ± 1.21 ng/mL, 9.06 ± 0.21 ng/mL, p less than 0.05). On estimating IL-22, IL-23, and TLR9, the results showed the concentrations of IL-22, IL-23, and TLR9 in the sera of breast cancer were significantly elevated as compared to those in the control groups. Expression of IL-22, IL-23, and TLR9 could be used as a diagnostic tumor biomarker.